Biotechnology Contract Manufacturing Market Size and Scope 2026 to 2035

Report Id: 2067 Pages: 179 Last Updated: 24 July 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Biotechnology Contract Manufacturing Market :

Biotechnology Contract Manufacturing Market By Service

  • Manufacturing
  • Formulation and Fill-Finish
  • Packaging and Labeling 
  • Other services

Biotechnology

Biotechnology Contract Manufacturing Market By Type

  • Biologic Drug Substance Manufacturing
  • Biologic Drug Product Manufacturing

Biotechnology Contract Manufacturing Market By Scale of Operation

  • Commercial Operations
  • Clinical Operations

Biotechnology Contract Manufacturing Market By Source

  • Mammalian Expression Systems
  • Non-Mammalian Expression Systems

Biotechnology Contract Manufacturing Market By Molecule

  • Monoclonal Antibodies
  • Cell Therapy & Gene Therapy
  • Antibody-Drug Conjugates (ADCs)
  • Vaccines
  • Therapeutic Peptides & Proteins
  • Other Molecule Types

Biotechnology Contract Manufacturing Market By Therapeutic Area

  • Oncology
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Infectious Diseases
  • Neurology
  • Other Therapeutic Areas

Biotechnology Contract Manufacturing Market By Region-

  • North America-
    • The US
    • Canada
  • Europe-
    • Germany
    • The UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific-
    • China
    • Japan
    • India
    • South Korea
    • South East Asia
    • Rest of Asia Pacific
  • Latin America-
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  •  Middle East & Africa-
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Biotechnology Contract Manufacturing Market Snapshot

Chapter 4. Global Biotechnology Contract Manufacturing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Service Estimates & Trend Analysis

5.1. By Service, & Market Share, 2024-2034

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Service:

5.2.1. Manufacturing

5.2.2. Formulation and Fill-Finish

5.2.3. Packaging and Labeling

5.2.4. Other services

Chapter 6. Market Segmentation 2: By Type Estimates & Trend Analysis

6.1. By Type & Market Share, 2024-2034

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type:

6.2.1. Biologic Drug Substance Manufacturing

6.2.2. Biologic Drug Product Manufacturing

Chapter 7. Market Segmentation 3: By Scale of Operation Estimates & Trend Analysis

7.1. By Scale of Operation & Market Share, 2024-2034

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Scale of Operation:

7.2.1. Commercial Operations

7.2.2. Clinical Operations

Chapter 8. Market Segmentation 4: By Source Estimates & Trend Analysis

8.1. By Source & Market Share, 2024-2034

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Source:

8.2.1. Mammalian Expression Systems

8.2.2. Non-Mammalian Expression Systems

Chapter 9. Market Segmentation 5: By Molecule Estimates & Trend Analysis

9.1. By Molecule & Market Share, 2024-2034

9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Molecule:

9.2.1. Monoclonal Antibodies

9.2.2. Cell Therapy & Gene Therapy

9.2.3. Antibody-Drug Conjugates (ADCs)

9.2.4. Vaccines

9.2.5. Therapeutic Peptides & Proteins

9.2.6. Other Molecule Types

Chapter 10. Market Segmentation 6: By Therapeutic Area Estimates & Trend Analysis

10.1. By Therapeutic Area & Market Share, 2024-2034

10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Therapeutic Area:

10.2.1. Oncology

10.2.2. Autoimmune Diseases

10.2.3. Cardiovascular Diseases

10.2.4. Metabolic Diseases

10.2.5. Infectious Diseases

10.2.6. Neurology

10.2.7. Other Therapeutic Areas

Chapter 11. Biotechnology Contract Manufacturing Market Segmentation 7: Regional Estimates & Trend Analysis

11.1. North America

11.1.1. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Service, 2021-2034

11.1.2. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Type, 2021-2034

11.1.3. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034

11.1.4. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Source, 2021-2034

11.1.5. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Molecule, 2021-2034

11.1.6. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034

11.1.7. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034

11.2. Europe

11.2.1. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Service, 2021-2034

11.2.2. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Type, 2021-2034

11.2.3. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034

11.2.4. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Source, 2021-2034

11.2.5. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Molecule, 2021-2034

11.2.6. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Therapeutic Area, 2021-2034

11.2.7. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034

11.3. Asia Pacific

11.3.1. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Service, 2021-2034

11.3.2. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Type, 2021-2034

11.3.3. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034

11.3.4. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Source, 2021-2034

11.3.5. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Molecule, 2021-2034

11.3.6. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Therapeutic Area, 2021-2034

11.3.7. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034

11.4. Latin America

11.4.1. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Service, (US$ Million) 2021-2034

11.4.2. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Type, (US$ Million) 2021-2034

11.4.3. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034

11.4.4. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Source, (US$ Million) 2021-2034

11.4.5. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034

11.4.6. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034

11.4.7. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034

11.5. Middle East & Africa

11.5.1. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Service, (US$ Million) 2021-2034

11.5.2. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Type, (US$ Million) 2021-2034

11.5.3. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034

11.5.4. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Source, (US$ Million) 2021-2034

11.5.5. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034

11.5.6. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034

11.5.7. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034

Chapter 12. Competitive Landscape

12.1. Major Mergers and Acquisitions/Strategic Alliances

12.2. Company Profiles

12.2.1 Lonza (Switzerland)
12.2.2 Samsung Biologics (South Korea)
12.2.3 Thermo Fisher Scientific, Inc. (US)
12.2.4 Catalent, Inc. (US)
12.2.5 JSR Corporation (Japan)
12.2.6 WuXi Biologics (China)
12.2.7 AbbVie, Inc. (US)
12.2.8 Boehringer Ingelheim International GmbH (Germany)
12.2.9 Eurofins Scientific (Luxembourg)
12.2.10 GenScript Biotech Corporation (US)
12.2.11 AGC, Inc. (Japan)
12.2.12 FUJIFILM Holding Corporation (Japan)
12.2.13 Merck KgaA (Germany)
12.2.14 Stelis
12.2.15 Recipharm Ab
12.2.16 Emergent
12.2.17 Shanghai Fosun Pharmaceutical Co., Ltd.
12.2.18 Lotte Biologics
12.2.19 Hepalink Group
12.2.20 Curia Global, Inc.
12.2.21 Jrs Pharma
12.2.22 Minapharm Pharmaceuticals
12.2.23 Rentschler Biopharma Se
12.2.24 Avid Bioservices, Inc.
12.2.25 Abzena Ltd.
12.2.26 Polyplus Transfection
12.2.27 Midas Pharma GMBH
12.2.28 Mabplex International Co., Ltd.
12.2.29 Asahi Kasei Corporation

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
8769
Security Code field cannot be blank!

Frequently Asked Questions

Biotechnology Contract Manufacturing Market Size is valued at USD 20.5 Bn in 2024 and is predicted to reach USD 46.6 Bn by the year 2034

Biotechnology Contract Manufacturing Market is expected to grow at a 8.7% CAGR during the forecast period for 2025-2034.

Jrs Pharma, Minapharm Pharmaceuticals, Rentschler Biopharma Se, Avid Bioservices, Inc., Abzena Ltd., Polyplus Transfection, Midas Pharma GMBH, Mabplex

Biotechnology Contract Manufacturing Market is segmented on the basis of service, type, scale of operation, source, molecule, and therapeutic area.

Asia Pacific region is leading the Biotechnology Contract Manufacturing Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying